The comparative characteristic of level of matrix metalloproteinase-9 and high-sensitive C-reactive protein indicators at comorbid course of arterial hypertension and chronic obstructive pulmonary disease

Authors

DOI:

https://doi.org/10.15587/2519-4798.2017.102579

Keywords:

matrix metalloproteinase- 9, high-sensitive С- reactive protein, chronic obstructive pulmonary disease

Abstract

The pathogenetic connection between the hypertonic disease and the chronic obstructive pulmonary disease (COPL) is little studied. The aim of research is to study the level of matrix metalloproteinase-9 and high sensitive C-protein indicators at the hypertonic disease and the chronic obstructive pulmonary disease. 

Methods. There were examined 40 patients: 30 with the diagnosis of hypertonic disease of II stage, combined with the chronic obstructive pulmonary disease, and 10 patients with the chronic obstructive pulmonary disease. Matrix metalloproteinase-9 and high sensitive C-protein levels in blood plasma and also parameters of elastic properties of the pulmonary artery were determined in all patients.

Results.  At the data analysis it was established that indicators of matrix metalloproteinase-9 and high sensitive C-protein were higher at the comorbidity of the hypertonic disease and the chronic obstructive pulmonary disease comparing with the group of isolated chronic obstructive pulmonary diseases. The analysis of elastic properties of the pulmonary artery demonstrated the essential increase of its hardness at comorbid states comparing with chronic obstructive pulmonary diseases.  

Conclusions. In patients with the hypertonic disease and the chronic obstructive pulmonary disease matrix metalloproteinase-9 and high sensitive C-protein levels increase comparing with isolated chronic obstructive pulmonary diseases that may testify to the role of these markers in the injury of target organs of the cardiovascular system. The monitoring of the dynamic of chronic obstructive pulmonary disease development and system inflammation is possible at the expanse of the determination of matrix metalloproteinase-9 and high sensitive C-protein levels

Author Biography

Oleg Yatsenko, Zaporizhzhia State Medical University Mayakovs'koho ave., 26, Zaporizhzhia, Ukraine, 69035

Postgraduate student

Department of internal medicine No 3

References

  1. Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. (Revised 2014). Available at: http://www.goldcopd.com
  2. Fabbri, L. M., Luppi, F., Beghe, B., Rabe, K. F. (2008). Complex chronic comorbidities of COPD. European Respiratory Journal, 31 (1), 204–212. doi: 10.1183/09031936.00114307
  3. Vertkin, A. L., Skotnikov, A. S., Gubzokova, O. M. (2013). Komorbidnost pri chronicheskoy obstructivnoi bolezni legkih: rol chronicheskogo sistemnogo vospaleniya I kliniko-farmakologocheskie nishi roflumilasta [Comorbidity in chronic obstructive pulmonary disease: role of chronic sytemic inflammation and clinical pharmacological opportunities roflumilast]. Treatming doctor, 9, 20–25.
  4. Karoli, N. A., Rebrov, A. P. (2006). Smertnost pri chronicheskoi obstrucvinoi bolezni legkih. Rol komorbidnosti [Mortality in chronic obstructive pulmonary disease. The role of comorbidity]. Clinical medicine, 7, 397–412.
  5. Hokanson, J. E. (2009). COPD and Coronary Heart Disease: Challenges in Understanding the Natural History of Common Complex Chronic Diseases. COPD: Journal of Chronic Obstructive Pulmonary Disease, 6 (3), 149–151. doi: 10.1080/15412550902994106
  6. Mannino, D. M., Thorn, D., Swensen, A., Holguin, F. (2008). Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Respiratory Journal, 32 (4), 962–969. doi: 10.1183/09031936.00012408
  7. Ovcharenko, S. I., Nersesyn, Z. N., Morozova, T. E. (2014). Chronicheskayao bstructivnaya bolezn legkih v sochetanii s arterialnoi gipertenziei efektivnost i bezopasnost primeneniya indapamida prolongirovannogo deistviya(arifon retard) [Chronic obstructive pulmonary disease combined with arterial hypertension: the efficacy and safety of application indapamide prolonged action (Arifon® retard)]. System hypertension, 2, 54–58.
  8. Pavlenko, V. I., Narishkina, S. V. (2012). Osobennosti sostoyaniya sistemi” oksidanti-antioksidanti” pri chronicheskoi obstructivnoi bolezni legkich sochetannoi s ishemicheskoi boleznu serdca [Features of the state system "oxidants-antioxidants" in chronic obstructive pulmonary disease combined with ischemic heart disease]. Profilactic medicine, 15 (1), 75.
  9. Maclay, J. D., McAllister, D. A., Mills, N. L., Paterson, F. P., Ludlam, C. A., Drost, E. M. et. al. (2009). Vascular Dysfunction in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 180 (6), 513–520. doi: 10.1164/rccm.200903-0414oc
  10. Waschki, B., Kirsten, A., Holz, O., Meyer, T., Lichtinghagen, R., Rabe, K. et. al. (2016). Angiopoietin-like protein 4 and cardiovascular function in COPD. BMJ Open Respiratory Research, 3 (1), e000161. doi: 10.1136/bmjresp-2016-000161
  11. Dinh, Q. N., Drummond, G. R., Sobey, C. G., Chrissobolis, S. (2014). Roles of Inflammation, Oxidative Stress, and Vascular Dysfunction in Hypertension. BioMed Research International, 2014, 1–11. doi: 10.1155/2014/406960
  12. Hancox, R. J., Gray, A. R., Sears, M. R., Poulton, R. (2016). Systemic inflammation and lung function: A longitudinal analysis. Respiratory Medicine, 111, 54–59. doi: 10.1016/j.rmed.2015.12.007
  13. Varga, J., Palinkas, A., Lajko, I., Horváth, I., Boda, K., Somfay, A. (2016). Pulmonary Arterial Pressure Response During Exercise in COPD: A Correlation with C-Reactive Protein (hsCRP). The Open Respiratory Medicine Journal, 10 (1), 1–11. doi: 10.2174/1874306401610010001
  14. Hurst, J. R., Donaldson, G. C., Perera, W. R., Wilkinson, T. M. A., Bilello, J. A., Hagan, G. W. et. al. (2006). Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 174 (8), 867–874. doi: 10.1164/rccm.200604-506oc
  15. Kwiatkowska, S., Noweta, K., Zieba, M., Nowak, D., Bialasiewicz, P. (2012). Enhanced Exhalation of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Patients with COPD Exacerbation: A Prospective Study. Respiration, 84 (3), 231–241. doi: 10.1159/000339417
  16. Pearson, T. A. (2003). Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107 (3), 499–511. doi: 10.1161/01.cir.0000052939.59093.45
  17. Bchir, S., Nasr, H. ben, Bouchet, S., Benzarti, M., Garrouch, A., Tabka, Z. et. al. (2016). Concomitant elevations of MMP-9, NGAL, proMMP-9/NGAL and neutrophil elastase in serum of smokers with chronic obstructive pulmonary disease. Journal of Cellular and Molecular Medicine. doi: 10.1111/jcmm.13057
  18. Samy, N., El-Maksoud, A., Khayyal, A. et. al. (2010). Clinical utility of biomarkers as predictors of lung function in chronic obstructive pulmonary disease. New York Science Journal, 3 (3), 25–32.
  19. Agusti, A. G. N., Noguera, A., Sauleda, J., Sala, E., Pons, J., Busquets, X. (2003). Systemic effects of chronic obstructive pulmonary disease. European Respiratory Journal, 21 (2), 347–360. doi: 10.1183/09031936.03.00405703
  20. Eickhoff, P., Valipour, A., Kiss, D., Schreder, M., Cekici, L., Geyer, K. et. al. (2008). Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 178 (12), 1211–1218. doi: 10.1164/rccm.200709-1412oc
  21. Barnes, P. J. (2000). Mechanisms in COPD: differences from asthma. Chest, 117, 10S–14S.
  22. Baraldo, S., Bazzan, E., Zanin, M. E., Turato, G., Garbisa, S., Maestrelli, P. et. al. (2007). Matrix Metalloproteinase-2 Protein in Lung Periphery Is Related to COPD Progression. Chest, 132 (6), 1733–1740. doi: 10.1378/chest.06-2819
  23. Vernooy, J. H. J., Lindeman, J. H. N., Jacobs, J. A., Hanemaaijer, R., Wouters, E. F. M. (2004). Increased Activity of Matrix Metalloproteinase-8 and Matrix Metalloproteinase-9 in Induced Sputum From Patients With COPD. Chest, 126 (6), 1802–1810. doi: 10.1378/chest.126.6.1802
  24. Gueders, M. M., Foidart, J.-M., Noel, A., Cataldo, D. D. (2006). Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: Potential implications in asthma and other lung diseases. European Journal of Pharmacology, 533 (1-3), 133–144. doi: 10.1016/j.ejphar.2005.12.082

Downloads

Published

2017-05-31

How to Cite

Yatsenko, O. (2017). The comparative characteristic of level of matrix metalloproteinase-9 and high-sensitive C-reactive protein indicators at comorbid course of arterial hypertension and chronic obstructive pulmonary disease. ScienceRise: Medical Science, (5 (13), 32–36. https://doi.org/10.15587/2519-4798.2017.102579

Issue

No. 5 (13) (2017)

Section

Medical Science

License

Copyright (c) 2017 Oleg Yatsenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.